Table 1 Characteristics of CHD patients

Age (years), mean ± SD

64.6 ± 9.1

64.2 ± 8.9

66.3 ± 10.0

0.199

Gender, No. (%)

0.155

 Female

40 (18.7)

36 (20.5)

4 (10.5)

 Male

174 (81.3)

140 (79.5)

34 (89.5)

BMI (kg/m²), mean ± SD

24.5 ± 3.6

24.5 ± 3.7

24.9 ± 3.1

0.462

Current smoke, No. (%)

55 (25.7)

43 (24.4)

12 (31.6)

0.361

Hypertension, No. (%)

150 (70.1)

119 (67.6)

31 (81.6)

0.088

Diabetes mellitus, No. (%)

63 (29.4)

43 (24.4)

20 (52.6)

0.001

Hypercholesteremia, No. (%)

135 (63.1)

104 (59.1)

31 (81.6)

0.009

Hyperuricemia, No. (%)

73 (34.1)

53 (30.1)

20 (52.6)

0.008

Family history of CAD, No. (%)

46 (21.5)

34 (19.3)

12 (31.6)

0.095

MAP (mmHg), median (IQR)

106.0 (97.0–115.0)

105.0 (96.3–116.8)

107.0 (102.0–111.3)

0.350

FBG (mmol/L), mean ± SD

5.8 ± 1.2

5.7 ± 1.3

6.2 ± 0.9

0.019

IRI, mean ± SD

2.25 ± 1.6

2.1 ± 1.5

3.0 ± 1.5

0.001

Scr (μmol/L), mean ± SD

82.7 ± 15.6

81.5 ± 14.8

88.1 ± 18.2

0.017

SUA (μmol/L), median (IQR)

333.6 (285.9–408.2)

333.3 (289.1–400.0)

365.3 (279.1–447.5)

0.309

TG (mmol/L), median (IQR)

1.8 (1.0–2.4)

1.8 (1.0–2.4)

1.9 (1.0–2.8)

0.587

TC (mmol/L), median (IQR)

4.6 (3.9–5.2)

4.5 (3.8–5.0)

4.6 (4.3–5.6)

0.069

LDL-C (mmol/L), mean ± SD

2.8 ± 0.6

2.7 ± 0.6

3.1 ± 0.6

0.002

HDL-C (mmol/L), mean ± SD

1.0 ± 0.2

1.0 ± 0.3

0.9 ± 0.2

0.024

HsCRP (mg/L), median (IQR)

4.7 (1.8–8.0)

3.9 (1.0–7.1)

7.4 (5.8–10.8)

 < 0.001

ESR (mm/L), median (IQR)

12.7 (6.7–20.8)

12.3 (5.8–20.7)

13.8 (8.3–26.1)

0.137

WBC (*10⁹/L), median (IQR)

6.1 (4.9–7.1)

6.1 (4.8–7.1)

6.3 (5.1–7.3)

0.367

Neutrophil (*10⁹/L), mean ± SD

3.4 ± 1.0

3.4 ± 1.0

3.6 ± 1.1

0.304

LVEF (%), median (IQR)

64.0 (59.8–70.0)

64.0 (60.0–70.0)

64.0 (57.8–70.0)

0.539

cTnI (pg/mL), median (IQR)

29.5 (17.8–47.7)

29.4 (15.3–46.9)

35.5 (23.5–57.2)

0.053

NT-proBNP (pg/mL), median (IQR)

76.5 (46.8–126.1)

75.6 (44.8–122.8)

78.1 (67.0–171.6)

0.039

Multivessel artery lesions, No. (%)

164 (76.6)

127 (72.2)

37 (97.4)

0.001

Patients with two target lesions, No. (%)

77 (36.0)

56 (31.8)

21 (55.3)

0.006

Target lesion at LAD, No. (%)

128 (59.8)

104 (59.1)

24 (63.2)

0.643

Target lesion at LCX, No. (%)

82 (38.3)

61 (34.7)

21 (55.3)

0.018

Target lesion at RCA, No. (%)

81 (37.9)

67 (38.1)

14 (36.8)

0.888

Stenosis degree of target lesion (%), median (IQR)

86.0 (82.0–89.0)

86.0 (82.0–89.0)

86.0 (83.0–91.0)

0.111

Length of target lesion (mm), median (IQR)

33.5 (26.0–40.0)

33.0 (26.0–39.0)

37.0 (29.0–46.3)

0.018

Length of stent (mm), median (IQR)

37.0 (30.0–43.3)

37.0 (28.3–43.0)

40.5 (33.0–49.0)

0.016

Diameter of stent (mm), median (IQR)

3.2 (2.9–3.4)

3.3 (2.9–3.4)

3.1 (3.0–3.3)

0.209

Time of stent dilation (s), median (IQR)

16.0 (13.0–18.0)

15.0 (14.0–18.0)

16.5 (12.0–20.0)

0.731

Pre-stent balloon dilation, No. (%)

66 (30.8)

56 (31.8)

10 (26.3)

0.505

Aspirin, No. (%)

214 (100.0)

176 (100.0)

38 (100.0)

–

Nitrates, No. (%)

214 (100.0)

176 (100.0)

38 (100.0)

–

Statins, No. (%)

214 (100.0)

176 (100.0)

38 (100.0)

–

β-receptor blockers, No. (%)

182 (85.0)

152 (86.4)

30 (78.9)

0.245

ACEIs/ARBs, No. (%)

134 (62.6)

116 (65.9)

18 (47.4)

0.032

Calcium channel blockers, No. (%)

68 (31.8)

58 (33.0)

10 (26.3)

0.425